Biotech Theravance Biopharma (Nasdaq: TBPH) this week reported another piece of good clinical data. The company reported that multiple studies conducted on VIBATIV—currently its only marketed drug—showed superior in vitro potency for VIBATIV against the S. aureus pathogens compared to other commercially available antibiotics. VIBATIV is already approved to treat S. aureus, but the company hopes the studies will differentiate it from competing antibiotics. Read More
Scott Chan moved from China to the U.S. with family at the age of ten. He passed the rigorous entrance exam and attended the merit-based Stuyvesant High School, widely held to be best public school in New York City. He earned undergraduate degrees from New York University followed by an MBA degree from the Zicklin School of Business at Baruch College.
Shortly thereafter Scott partnered with Dr. Stephen Leeb on numerous financial publications. Today, he serves as the lead analyst for Real World Investing and The Complete Investor.
Mr. Chan is an avid baseball fan and enjoys outdoor activities in his spare time. A multicultural person, he reads Chinese and speaks fluent Mandarin and Cantonese Chinese.
Analyst Articles
Yesterday we recommended buying to open a position in the CurrencyShares Japanese Yen ETF (NYSE: FXY) July 21, 2017 $90 call option, at a suggested limit price of 55 cents. As noted in the Trade Alert, this is not an indicator-based trade. The trade is intended as a short-term hedge… Read More
Investor activism can be a positive by shaking things up at a struggling company and holding incumbent management accountable. Read More
After a weak March, then a strong April, U.S. hiring activity again fell lower than expected in May. Today’s Labor Department monthly report shows that non-farm payrolls only increased by 138,000, well below the 182,000 consensus economist projection. Furthermore, the estimates for March and April were revised downward by a… Read More
By far, the gold and gold stocks indicators are our most bearish indicators right now. Our gold stocks indicator has actually become even more bearish, and our VanEck Vectors Gold Miners ETF (GDX) December 23 put is still a “buy” for readers who may have missed the original… Read More
This week we review our reference funds’ latest moves vis-à-vis our Brain Trust Profits stocks to see how the Wall Street gurus’ holdings of our stocks have changed, if at all. Marcato Capital Management has upped its position in AAR Corp (NYSE: AIR) by roughly 324,000 shares,… Read More
- May 24, 2017
-
Download Issue
Editor’s Note: In case you missed the earlier announcement, Aggressive Trader has a new home! You can log into our new website here. The outage at our email service provider that prevented us from sending the Trade Alert to buy the VanEck Vectors Gold Miners… Read More
Average Annualized Return Per Closed Trade: 15.2% Average Return Per Closed Trade: 14.1% Average Holding Period: 340 days On Wednesday, the market had its worst one day decline since the election, as an FBI memo leaked to the press shows that President Trump had asked… Read More
Sell Innoviva (INVA) Seth Klarman’s Baupost Group has sold more than 90 percent of its position in Innoviva (INVA). Although the company has promised to review its expense control and compensation structures after the proxy fight, which it won, after careful consideration, we have decided to follow Baupost out the… Read More
Average Annualized Return Per Closed Trade: 17.9% Average Return Per Closed Trade: 15.5% Average Holding Period: 320 days Sotheby’s (BID) reported another solid quarter this week. Although its fiscal first quarter (ended March 31) tends to be seasonally weak compared to others, adjusted for non-recurring items, the company… Read More